Adimab, Inc. Lands Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea916dda-1b46-4da8-97cb-a8ce2fed1381&Preview=1 -
Date
3/25/2008 -
Company Name
Adimab, Inc. -
Mailing Address
16 Cavendish Court Lebanon, NH 03766 -
Company Description
Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners. -
Website
http://www.adimab.com -
Transaction Type
Venture Equity -
Transaction Amount
Undisclosed -
Transaction Round
Series B -
Proceeds Purposes
“Since Adimab’s founding in 2007 we have experienced significant interest from both potential partners and investment groups,” said Errik Anderson, Vice President of Operations and Finance. “This financing, at a significant step up in valuation, allows us to confidently build the capacity to execute multiple programs with our partners.” -
M&A Terms
-
Venture Investor
Polaris Venture Partners -
Venture Investor
SV Life Sciences
